Related Experiment Video

Updated: Feb 27, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

Targeting the α4-α5 interface of RAS results in multiple levels of inhibition

Russell Spencer-Smith1,2,3, Lie Li1,2,3, Sheela Prasad1

  • 1a Department of Pharmacology, University of Illinois at Chicago , Chicago , IL , USA.

Small Gtpases
|July 11, 2017
PubMed

Insights

A novel monobody, NS1, targets RAS proteins to inhibit cancer growth. NS1 disrupts RAS signaling by affecting RAS GTP levels and isoform-specific interactions with RAF, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • RAS proteins are crucial in cancer development, but targeting them is challenging due to their structure and function.
  • Developing effective RAS-targeted therapeutics remains a significant goal in cancer research.

Purpose of the Study:

  • To investigate the mechanism of action of the monobody NS1, a potential RAS-targeted therapeutic.
  • To elucidate the isoform-specific effects of NS1 on RAS:RAF interactions and RAS signaling pathways.

Main Methods:

  • Utilized a monobody (NS1) that binds to the RAS protein interface.
  • Assessed NS1's effects on RAS dimerization, nanoclustering, and RAF activation.
  • Analyzed isoform-specific interactions between RAS and RAF, focusing on H-RAS and K-RAS.
  • Measured RAS GTP levels to evaluate wild-type RAS function inhibition.

Main Results:

  • NS1 inhibits RAS signaling and oncogenic transformation by preventing RAS dimerization and nanoclustering.
  • NS1 exhibits isoform-specific effects, reducing K-RAS interaction with RAF and its plasma membrane localization, attributed to distinct RAS hypervariable regions.
  • NS1 inhibits wild-type RAS function by decreasing RAS GTP levels.

Conclusions:

  • NS1 disrupts RAS signaling through a complex mechanism beyond just inhibiting dimerization and nanoclustering.
  • The distinct hypervariable regions of RAS isoforms contribute to NS1's isoform-specific effects on RAS:RAF interactions.
  • NS1 represents a promising therapeutic candidate for targeting RAS-driven cancers.
Keywords:
H-RASK-RASNS1 monobodyRAS chimeraRAS dimerizationRAS inhibitorRAS nanoclustering

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K
Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening05:54

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

9.1K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.6K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.8K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
18.7K